Patent ID: 8486913
Filing Date: 2013-07-16
Classification: A61K,A61P,C12N,C12Q

Abstract:
1. A method of decreasing expression of a transcription factor gene product from the homeobox gene family (HOXA1) in a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product, comprising administering an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof to the subject sufficient to decrease expression of the HOXA1 gene product in the subject, wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of: acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), multiple myeloma (MM), and chronic myelogenous leukemia (CML).